Loss of Bone Density with Inhaled Corticosteroids
Main Category: COPDAlso Included In: Bones / Orthopedics
Article Date: 16 Dec 2004 - 9:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Study participants with mild to moderate chronic obstructive pulmonary disease (COPD) who used 1,200 micrograms per day over 3 years of an inhaled corticosteroid, triamcinalon, in an attempt to slow lung function decline showed reduced bone density in both the lumbar spine and neck of the femur (thigh).
The researchers investigated bone metabolism in COPD in 412 subgroup participants involved in Lung Health Study II. All subjects, who were either current smokers or recent quitters, underwent bone mineral density scans of the hip and lumbar spine with dual-energy X-ray absorptiometry at the start of the study, after 1 year, and at the end of year 3. (In COPD, patients have persistent obstruction of the airways associated with either emphysema or chronic bronchitis, caused by years of smoking.)
The reductions were 1.78 percent in femoral neck bone mass density and 1.33 percent in lumbar spine bone mass density. The declines occurred in both the men and women patients who were from 55 to 57 years old. Good adherence to therapy (more than 9 puffs of inhaled corticosteroid per day over 3 years) was seen in almost 47 percent of the patients.
The authors said that there was little or no decline in bone mass density until after the first year of the study, but reductions did occur during the second and third years of the trial. Since smoking prevalence is high in persons with COPD, the authors urged doctors to encourage patients to quit. The study appears in the second issue for December 2004 of the American Thoracic Society's peer-reviewed American Journal of Respiratory and Critical Care Medicine.
American Thoracic Society Journal news tips for December 2004 (second issue)
For the complete text of these articles, please see the American Thoracic Society Online Web Site at http://www.atsjournals.org. For either contact information or to request a complimentary journalist subscription to ATS journals online, or if you would like to add your name to the Society's twice monthly journal news e-mail list, contact Cathy Carlomagno at 212-315-6442, or by e-mail at ccarlomagno@thoracic.org.
Contact: Cathy Carlomagno
ccarlomagno@thoracic.org
212-315-6442
American Thoracic Society
Visit our copd section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/17887.php>
APA
http://www.medicalnewstoday.com/releases/17887.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



